217 related articles for article (PubMed ID: 37578310)
1. Exploratory analysis of 64 CuCl 2 PET-CT imaging in carcinoma prostate and its comparison with 68 Ga-PSMA-11 and 18 F-FDG PET-CT.
Nazar AK; Kalshetty A; Chakravarty R; Chakraborty S; Basu S
Nucl Med Commun; 2023 Oct; 44(10):910-923. PubMed ID: 37578310
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Potential role of
Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
[TBL] [Abstract][Full Text] [Related]
4.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of
Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
[TBL] [Abstract][Full Text] [Related]
6. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
[TBL] [Abstract][Full Text] [Related]
7. 68 Ga-PSMA-11 PET/CT and 64 CuCl 2 PET/CT Help in Identifying Rare Metastatic Site of Penile Shaft in a Patient of Carcinoma Prostate.
Verma P; Nazar A; Jadhav S; Basu S
Clin Nucl Med; 2024 Jan; 49(1):e10-e11. PubMed ID: 37976433
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
9. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
10. Total-Body
Pomykala KL; Czernin J; Grogan TR; Armstrong WR; Williams J; Calais J
J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
[TBL] [Abstract][Full Text] [Related]
11. Prospective intra-individual blinded comparison of [
Pattison DA; Debowski M; Gulhane B; Arnfield EG; Pelecanos AM; Garcia PL; Latter MJ; Lin CY; Roberts MJ; Ramsay SC; Thomas PA
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):763-776. PubMed ID: 34383089
[TBL] [Abstract][Full Text] [Related]
12. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
13.
Parghane RV; Basu S
J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 68Ga-PSMA-HBED-CC and 18F-FDG PET/CT in the Evaluation of Adenoid Cystic Carcinoma-A Prospective Study.
Shamim SA; Kumar N; Arora G; Kumar D; Pathak A; Thakkar A; Sikka K; Singh CA; Kakkar A; Bhalla AS
Clin Nucl Med; 2023 Nov; 48(11):e509-e515. PubMed ID: 37812520
[TBL] [Abstract][Full Text] [Related]
15. 68 Ga-PSMA-11 and 18 F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate.
Qiu S; Dong A; Zhu Y; Zuo C
Clin Nucl Med; 2022 Sep; 47(9):836-838. PubMed ID: 35439204
[TBL] [Abstract][Full Text] [Related]
16. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
17. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
18. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 18 F-PSMA-1007 PET/CT With 68 Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer.
Chandekar KR; Singh H; Kumar R; Kumar S; Kakkar N; Mittal BR; Singh SK
Clin Nucl Med; 2023 Jan; 48(1):e1-e8. PubMed ID: 36240786
[TBL] [Abstract][Full Text] [Related]
20. A prospective intra-individual comparison of [
Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
